MUC1 and Familial prostate cancer: Some of those aforementioned vaccines have been able to reach different phases of clinical trials, e.g., a hexavalent vaccine construct, incorporating GM2, globo H, Ley, clustered Thomsen nouveau (Tn), clustered Thomsen-Friedenreich (TF), and glycosylated mucin 1 (MUC1) antigens have been used for the treatment of phase II prostate cancer patients [9].